Modelling the impact of prevention strategies on cervical cancer incidence in South Africa
- 24 June 2021
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 149 (8) , 1564-1575
Abstract
In 2020, the World Health Organisation (WHO) published a strategy to eliminate cervical cancer as a public health concern. In South Africa, despite having a national screening policy in place since 2000, diagnosed cervical cancer incidence has shown no signs of decline. We extend a previously developed individual‐based model for human immunodeficiency virus (HIV) and human papillomavirus (HPV) infection to include progression to cervical cancer. The model accounts for future reductions in HIV incidence and prevalence and includes a detailed cervical cancer screening algorithm, based on individual‐level data from the public health sector. We estimate the impact of the current prevention programme and alternative screening scenarios on cervical cancer incidence. The South African screening programme prevented 8600 (95%CI 4700‐12 300) cervical cancer cases between 2000 and 2019. At current levels of prevention (status quo vaccination, screening, and treatment), age‐standardised cervical cancer incidence will reduce from 49.4 per 100 000 women (95%CI 36.6‐67.2) in 2020, to 12.0 per 100 000 women (95%CI 8.0‐17.2) in 2120. Reaching WHO's prevention targets by 2030 could help South Africa reach elimination (at the 10/100 000 threshold) by 2077 (94% probability of elimination by 2120). Using new screening technologies could reduce incidence to 4.7 per 100 000 women (95%CI 2.8‐6.7) in 2120 (44% probability of elimination at the 4/100 000 threshold). HPV vaccination and decreasing HIV prevalence will substantially reduce cervical cancer incidence in the long term, but improvements to South Africa's current screening strategy will be required to prevent cases in the short term. Switching to new screening technologies will have the greatest impact.Keywords
Funding Information
- Cancer Association of South Africa
- World Health Organization
This publication has 29 references indexed in Scilit:
- Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trialsThe Lancet Oncology, 2015
- Distribution of Human Papillomavirus Genotypes among HIV-Positive and HIV-Negative Women in Cape Town, South AfricaFrontiers in Oncology, 2014
- Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: A partially-blind randomised placebo-controlled studyVaccine, 2013
- Impact of introduction of a colposcopy service in a rural South African sub-district on uptake of colposcopySouth African Journal of Obstetrics and Gynaecology, 2013
- Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort studyThe Lancet Oncology, 2011
- The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South AfricaVaccine, 2009
- Viral Determinants of Human Papillomavirus Persistence following Loop Electrical Excision Procedure Treatment for Cervical Intraepithelial Neoplasia Grade 2 or 3Cancer Epidemiology, Biomarkers & Prevention, 2007
- Challenges in implementing a cervical screening program in South AfricaCancer Detection Prevention, 2006
- The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literatureCancer Treatment Reviews, 2004
- Human Immunodeficiency Virus Infection and Invasive Cervical Cancer in South AfricaGynecologic Oncology, 2000